Tranexamic acid in adenotonsillectomy in children: a double-blind randomized clinical trial

Int J Pediatr Otorhinolaryngol. 2012 Oct;76(10):1401-5. doi: 10.1016/j.ijporl.2012.04.028. Epub 2012 Jun 16.

Abstract

Objectives: Adenotonsillectomy is one of the most common surgical procedures in pediatric otolaryngology, in which bleeding is a potential complication. We evaluated the efficacy of intravenous tranexamic acid in reducing intraoperative bleeding volume, and bleeding in the following 10 postoperative days in children who underwent adenotonsillectomy.

Design: Double-blind, randomized placebo-controlled trial.

Setting: Tertiary hospital.

Patients: Ninety-five children of both sexes between four and twelve years old who underwent adenotonsillectomy due to adenotonsillar hyperplasia.

Interventions: Intravenous tranexamic acid in the preoperative and at the eighth and the sixteenth hours of the postoperative periods.

Main outcome measure: Bleeding volume was measured in milliliters (mL) at the end of the procedure, and bleeding events were registered in the following 10 postoperative days.

Results: There was no statistically significant reduction in bleeding volume with the use of tranexamic acid (mean ± standard deviation, 135.13 ± 71.44 [tranexamic acid] versus 158.21 ± 88.09 [placebo]; P=0.195). No difference was observed in the incidence of postoperative bleeding in the 10 postoperative days, but the sample size is insufficient to exclude a type 2 error.

Conclusions: There is no benefit in the use of tranexamic acid for reducing bleeding during the transoperative period of adenotonsillectomy in children. More studies with a greater sample are required to evaluate the benefit of tranexamic acid in postoperative bleeding.

Trial registration: ClinicalTrials.gov NCT01228136.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adenoidectomy*
  • Antifibrinolytic Agents / therapeutic use*
  • Blood Loss, Surgical / statistics & numerical data
  • Child
  • Child, Preschool
  • Double-Blind Method
  • Female
  • Hemorrhage / prevention & control*
  • Hemostasis, Surgical
  • Humans
  • Injections, Intravenous
  • Intraoperative Complications / prevention & control
  • Linear Models
  • Male
  • Postoperative Complications / prevention & control
  • Tonsillectomy*
  • Tranexamic Acid / therapeutic use*

Substances

  • Antifibrinolytic Agents
  • Tranexamic Acid

Associated data

  • ClinicalTrials.gov/NCT01228136